Clinical Trial Update: Extension Study Evaluating The Safety And Tolerability of AMX0035 [Phase 3]

View source ↗

Summary

This document reports the completion of a Phase 3 extension study evaluating the safety and tolerability of AMX0035 in amyotrophic lateral sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• AMX0035 (sodium phenylbutyrate and tauroursodeoxycholic acid)

Snippet

Sponsor: Amylyx Pharmaceuticals Inc. | Conditions: Amyotrophic Lateral Sclerosis | Phase 3 | Status: COMPLETED